Avita Medical Inc (Avita Medical) is a therapeutic acute wound care company focused on developing solutions to optimize skin restoration procedures. The company’s key statistics include 13 randomized control trials, over 390 publications and presentations, and more than 30,000 patients treated.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Avita Medical's R&D arm focuses on advancing innovative products and building a comprehensive portfolio of solutions, as well as developing clinical applications to advance the management of wound care. The company conducts clinical studies to provide further efficacy and health economic evidence. The company aims to develop solutions for the potential treatment of a wide range of skin injuries or defects using the RECELL System. Avita Medical is dedicated to product development to ensure the evolution of the RECELL platform and to maintain robust patent protection. The company has developed RECELL GO, a next-generation autologous cell harvesting device, and RECELL GO mini, designed for smaller wounds. As of December 2025, Avita Medical had 6 issued U.S. utility patents, 1 issued U.S. design patent, 7 pending U.S. utility patent applications, and 5 pending U.S. design patent applications. Additionally, the company had various granted and pending patents in countries such as Australia, Brazil, Canada, China, Hong Kong, Japan, Europe, and New Zealand. In FY2025, the company spent US$20.8 million on its R&D activities, which as a percentage of revenue stood at 29%.